- Home
- ILPT vs TVRD Comparison
ILPT vs TVRD Comparison
Compare ILPT & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILPT
- TVRD
- Stock Information
- Founded
- ILPT 2017
- TVRD 2017
- Country
- ILPT United States
- TVRD United States
- Employees
- ILPT N/A
- TVRD N/A
- Industry
- ILPT Real Estate Investment Trusts
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- ILPT Real Estate
- TVRD Health Care
- Exchange
- ILPT Nasdaq
- TVRD Nasdaq
- Market Cap
- ILPT 174.6M
- TVRD 166.5M
- IPO Year
- ILPT 2018
- TVRD N/A
- Fundamental
- Price
- ILPT $3.15
- TVRD $25.61
- Analyst Decision
- ILPT Buy
- TVRD Strong Buy
- Analyst Count
- ILPT 2
- TVRD 1
- Target Price
- ILPT $10.00
- TVRD $39.00
- AVG Volume (30 Days)
- ILPT 320.9K
- TVRD 39.8K
- Earning Date
- ILPT 04-29-2025
- TVRD 05-21-2025
- Dividend Yield
- ILPT 1.27%
- TVRD N/A
- EPS Growth
- ILPT N/A
- TVRD N/A
- EPS
- ILPT N/A
- TVRD N/A
- Revenue
- ILPT $441,992,000.00
- TVRD N/A
- Revenue This Year
- ILPT $8.07
- TVRD N/A
- Revenue Next Year
- ILPT N/A
- TVRD N/A
- P/E Ratio
- ILPT N/A
- TVRD N/A
- Revenue Growth
- ILPT 0.61
- TVRD N/A
- 52 Week Low
- ILPT $2.45
- TVRD $8.14
- 52 Week High
- ILPT $5.45
- TVRD $31.32
- Technical
- Relative Strength Index (RSI)
- ILPT 58.47
- TVRD N/A
- Support Level
- ILPT $2.77
- TVRD N/A
- Resistance Level
- ILPT $3.15
- TVRD N/A
- Average True Range (ATR)
- ILPT 0.17
- TVRD 0.00
- MACD
- ILPT 0.08
- TVRD 0.00
- Stochastic Oscillator
- ILPT 93.01
- TVRD 0.00
About ILPT Industrial Logistics Properties Trust of Beneficial Interest
Industrial Logistics Properties Trust is a real estate investment trust. It owns and leases industrial and logistics properties throughout the United States. The company's investment portfolio includes industrial lands in Hawaii and industrial and logistics properties in other states. Rental revenue is earned from Hawaii Properties and Mainland Properties.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.